Fractyl shares fall 48% even as Revita meets six-month REMAIN-1 endpoint

Fractyl Health said on October 16 that the registrational cohort of its REMAIN-1 study met its six-month co-primary endpoint. Patients who had a single Revita procedure after stopping tirzepatide kept about 80% of their drug-induced weight loss, against 67% for patients who had a sham procedure.

Investors did not reward the result. According to RTTNews, Fractyl shares fell about 48% to around $2.14 on October 16, from a prior close of $4.16, on volume of 10.59 million shares against an average of about 147,000.

The details

REMAIN-1 is randomized, double-blind and sham-controlled, at more than 30 US sites. It enrolled 308 adults with a BMI of 30 to 45, without type 2 diabetes and with no prior GLP-1 use. Everyone took tirzepatide until they lost at least 15% of body weight, then stopped and was randomized 2:1 to Revita or sham, HCPLive reported.

At six months, least-squares mean weight regain was 5.1% of body weight with Revita and 8.2% with sham (p=0.0023), according to the company's 8-K. In a post hoc look, 32% of Revita patients were weight-stable or still losing versus 18% on sham, and patients with 20 cm or more of treated duodenum regained 3.8%.

The second co-primary endpoint is read at 12 months: the share of Revita patients who keep at least 5% total body weight loss from their pre-tirzepatide weight, measured against an FDA-set performance goal of more than 50%. Through a September 24 data cutoff, there were no device- or procedure-related serious adverse events, and 94% of related adverse events occurred within seven days of the procedure.

Context

The stock was already down sharply this year. In January, Fractyl reported 4.5% six-month regain with Revita versus 7.5% for control, and a class action complaint says shares fell more than 68%, according to a Benzinga report reposted by KuCoin. The same report said Fractyl faces a securities class action covering buyers from January 13, 2025, to January 29, 2026, and that Morgan Stanley cut its estimated probability of success for Revita from 50% to 35%.

The regulatory plan has also changed. In September 2025, Fractyl talked about a potential PMA filing in the second half of 2026. It now plans a De Novo application. "We intend to initiate our De Novo marketing application to the FDA in late Q4 2026," chief executive Harith Rajagopalan said in the release. Revita holds FDA Breakthrough Device designation and is CE marked in the EU and UK, per HCPLive.

What it means for investors

The trial won on its first test, but the gap was 3.1 percentage points of body weight at six months. RTTNews gave no reason for the selloff. Most of the eye-catching numbers, such as the dose-response by ablation length, are post hoc.

The larger test comes next. The 12-month responder endpoint is a fixed bar of more than 50%, and the company has not yet reported how many patients are on track to clear it. Other risks are the pending class action, FDA review of a De Novo request, and payment: a Category III CPT code takes effect January 1, 2027, and the company is aiming for a US launch in early 2028.

What to watch

Fractyl plans to file its De Novo application in late fourth quarter 2026. Topline one-year data, including the second co-primary endpoint, are expected in the first quarter of 2027.

Report an error

Companies in this story

GUTSFractyl Health, Inc.NASDAQ · United StatesOpen the desk